Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.
Llevamos a cabo un análisis longitudinal y transversal de la sintomatología depresiva en iPrEx, del estudio de placebo controlado, con selección de brazo al azar.
In this report from the GBD 2015, we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy.
The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to asess these factors in a cohort of HIV-negative people at risk of infection.